Provectus Biopharmaceuticals's current cash is $220K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), PVCT shows a current cash of $220K. That compares with $390K in the prior-year period — down 42.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PVCT's current cash is now $220K (was $390K) — a 42.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Provectus Biopharmaceuticals is outperforming or lagging.
Tracking PVCT's current cash over time shows whether Provectus Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $220K That compares with $390K in the prior-year period — down 42.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Provectus Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $220K) with ownership activity and broader fundamentals.
Provectus Biopharmaceuticals's current cash is $220K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.